RxDoctor Payments DataLook up a doctor →

Pearl Grimes, MD

Dermatology · Los Angeles, CANPI 1790702751

Payments from drug & device makers

$1,553,425in general payments, 2019–2025

Across 497 payments — averaging $3125.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$976K
  • AbbVie$263K
  • Pfizer$175K
  • Aclaris Therapeutics, Inc.$56K
  • Taro Pharmaceuticals USA, Inc.$47K
  • Eli Lilly$24K
  • plus $12K from 7 others
$136,811in research payments, 2019–2025

Across 1 payment — averaging $136,811 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$137K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,553,425 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$212,505
Medicare patients
251
Services billed
1,221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other dermatology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →